The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Obstructive Sleep Apnea and Obesity

Purpose of Review Strong associations exist between obstructive sleep apnea (OSA) and obesity. Prior studies have demonstrated that weight reduction in people with OSA and obesity improves severity of OSA. Until recently, there were no approved pharmacotherapies for OSA. We aim to review recent literature on GLP-1 receptor agonists and GIP agonists and their potential role in the management of OSA. Recent Findings Novel pharmacotherapies developed to target obesity include glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. These therapies have proven to be helpful in many comorbid conditions, with published studies suggesting a benefit in OSA. Summary GLP-1 receptor agonists and GIP agonists are emerging potential therapies for OSA and associated cardiometabolic risk.